Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions

Akk, 2005, Neurosteroid access to the GABAA receptor, J Neurosci, 25, 11605, 10.1523/JNEUROSCI.4173-05.2005

Almeida, 2005, Single-dose and steady-state pharmacokinetics of eslicarbazepine acetate (BIA 2-093) in healthy elderly and young subjects, J Clin Pharmacol, 45, 1062, 10.1177/0091270005279364

Almeida, 2008, Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment, Eur J Clin Pharmacol, 64, 267, 10.1007/s00228-007-0414-1

Almeida, 2007, Eslicarbazepine acetate (BIA 2-093), Neurotherapeutics, 4, 88, 10.1016/j.nurt.2006.10.005

Alves, 2007, Enantioselective HPLC-UV method for determination of eslicarbazepine acetate (BIA 2-093) and its metabolites in human plasma, Biomed Chromatogr, 21, 1127, 10.1002/bmc.858

Ambrosio, 2000, Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024, Eur J Pharmacol, 406, 191, 10.1016/S0014-2999(00)00659-2

Ambrosio, 2001, Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels, Biochem Pharmacol, 61, 1271, 10.1016/S0006-2952(01)00584-6

Arends, 1994, Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect, Epilepsy Res, 18, 91, 10.1016/0920-1211(94)90001-9

Armijo, 2005, Ion channels and epilepsy, Curr Pharm Des, 11, 1975, 10.2174/1381612054021006

Arroyo, 2007, Rufinamide, Neurotherapeutics, 4, 155, 10.1016/j.nurt.2006.11.006

Bauer, 2001, Losigamone add-on therapy in partial epilepsy: a placebo-controlled study, Acta Neurol Scand, 103, 226, 10.1034/j.1600-0404.2001.103004226.x

Baulac, 2003, Efficacy and safety of Losigamone in partial seizures: a randomized double-blind study, Epilepsy Res, 55, 177, 10.1016/S0920-1211(03)00108-6

Benes, 1999, Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives, J Med Chem, 42, 2582, 10.1021/jm980627g

Ben-Menachem, 2007, Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures, Epilepsia, 48, 1308, 10.1111/j.1528-1167.2007.01188.x

Ben-Menachem, 2004, Pregabalin pharmacology and its relevance to clinical practice, Epilepsia, 45, S13, 10.1111/j.0013-9580.2004.455003.x

Bennett, 2007, Seletracetam (UCB 44212), Neurotherapeutics, 4, 117, 10.1016/j.nurt.2006.11.014

Berry, 2005, Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC, Ther Drug Monit, 27, 451, 10.1097/01.ftd.0000158874.54100.1a

Bialer, 2001, Progress report on new antiepileptic drugs: a summary of the Fifth Eilat Conference (EILAT V), Epilepsy Res, 43, 11, 10.1016/S0920-1211(00)00171-6

Bialer, 2002, Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI), Epilepsy Res, 51, 31, 10.1016/S0920-1211(02)00106-7

Bialer, 2007, Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII), Epilepsy Res, 73, 1, 10.1016/j.eplepsyres.2006.10.008

Bialer, 2004, Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII), Epilepsy Res, 61, 1, 10.1016/j.eplepsyres.2004.07.010

Bialer, 2006, New antiepileptic drugs that are second generation to existing antiepileptic drugs, Expert Opin Investig Drugs, 15, 637, 10.1517/13543784.15.6.637

Biber, 1996, Pharmacokinetics of losigamone, a new antiepileptic drug, in healthy male volunteers, Int J Clin Pharmacol Ther, 34, 6

Binda, 2007, Structures of human monoamine oxidase B complexes with selective noncovalent inhibitors: safinamide and coumarin analogs, J Med Chem, 50, 5848, 10.1021/jm070677y

Biton, 2008, Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures, Epilepsia, 49, 418, 10.1111/j.1528-1167.2007.01317.x

Blotnik, 1997, The disposition of valproyl glycinamide and valproyl glycine in rats, Pharm Res, 14, 873, 10.1023/A:1012143631873

Boucher, 1996, Fosphenytoin: a novel phenytoin prodrug, Pharmacotherapy, 16, 777

Boucher, 1996, The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients, Pharmacotherapy, 16, 638

Brodie, 2005, Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy, Epilepsia, 46, 1407, 10.1111/j.1528-1167.2005.19204.x

Buchwald, 2005, Unified pharmacogenetics-based parentmetabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans, J Pharmacokinet Pharmacodyn, 32, 377, 10.1007/s10928-005-0001-y

Caccia, 2006, Safinamide: from molecular targets to a new anti-Parkinson drug, Neurology, 67, S18, 10.1212/WNL.67.7_suppl_2.S18

Carter, 1997, Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3(-hydroxy-3(-methyl-5(-pregnan-20-one), a selective, high-affinity, steroid modulator of the g-aminobutyric acidA receptor, J Pharmacol Exp Ther, 280, 1284

Chadwick, 2000, Remacemide hydrochloride: a placebo-controlled, one month, double-blind assessment of its safety, tolerability and pharmacokinetics as adjunctive therapy in patients with epilepsy, Seizure, 9, 544, 10.1053/seiz.2000.0448

Chappell, 2002, A crossover, add-on trial of talampanel in patients with refractory partial seizures, Neurology, 58, 1680, 10.1212/WNL.58.11.1680

Chien, 2006, Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults, Epilepsia, 47, 1830, 10.1111/j.1528-1167.2006.00815.x

Chien, 2007, An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid, Epilepsia, 48, 1328, 10.1111/j.1528-1167.2007.01037.x

Chiron, 2007, Stiripentol, Neurotherapeutics, 4, 123, 10.1016/j.nurt.2006.10.001

Chiron, 2000, Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group, Lancet, 356, 1638, 10.1016/S0140-6736(00)03157-3

Choi, 1996, Synthesis and anticonvulsant activities of N-Benzyl-2-acetamidopropionamide derivatives, J Med Chem, 39, 1907, 10.1021/jm9508705

Choi, 1996, The anticonvulsant activities of functionalized N-benzyl 2-acetamidoacetamides. The importance of the 2-acetamido substituent, Bioorg Med Chem, 4, 2105, 10.1016/S0968-0896(96)00225-8

Dahan, 2008, The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration, J Control Release, 126, 1, 10.1016/j.jconrel.2007.10.025

Dal Bo, 2006, Bioassay of safinamide in biological fluids of humans and various animal species, Arzneimittelforschung, 56, 814

Dasgupta, 2001, Rapid in vitro conversion of fosphenytoin into phenytoin in sera of patients with liver disease: role of alkaline phosphatase, J Clin Lab Anal, 15, 244, 10.1002/jcla.1035

Davies, 1997, Remacemide hydrochloride: a novel antiepileptic agent, Gen Pharmacol, 28, 499, 10.1016/S0306-3623(96)00280-7

Deeks, 2006, Rufinamide, CNS Drugs, 20, 751, 10.2165/00023210-200620090-00007

Deshpande, 2008, The novel antiepileptic drug carisbamate (RWJ 333369) is effective in inhibiting spontaneous recurrent seizure discharges and blocking sustained repetitive firing in cultured hippocampal neurons, Epilepsy Res, 79, 158, 10.1016/j.eplepsyres.2008.01.002

Dienel, 2004, Influence of losigamone on the pharmacokinetics of a combined oral contraceptive in healthy female volunteers, Arzneimittelforschung, 54, 152

Dimpfel, 1995, Effects of the anticonvulsant losigamone and its isomers on the GABAA receptor system, Epilepsia, 36, 983, 10.1111/j.1528-1157.1995.tb00956.x

Dooley, 2002, Preferential action of gabapentin and pregabalin at P/Q-type voltage-sensitive calcium channels: inhibition of K+-evoked [3H]-norepinephrine release from rat neocortical slices, Synapse, 45, 171, 10.1002/syn.10094

Dooley, 2000, Stimulusdependent modulation of [3H]norepinephrine release from rat neocortical slices by gabapentin and pregabalin, J Pharmacol Exp Ther, 295, 1086

Doty, 2007, Lacosamide, Neurotherapeutics, 4, 145, 10.1016/j.nurt.2006.10.002

Draguhn, 1997, Losigamone decreases spontaneous synaptic activity in cultured hippocampal neurons, Eur J Pharmacol, 325, 245, 10.1016/S0014-2999(97)00121-0

Eckstein, 1995, Determination of a novel α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor antagonist (LY300164) and its N-acetyl metabolite in mouse, rat, dog, and monkey plasma using highperformance liquid chromatography with ultraviolet detection, J Chromatogr B Biomed Appl, 668, 153, 10.1016/0378-4347(95)00058-Q

Elger, 2007, Eslicarbazepine acetate: a doubleblind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures, Epilepsia, 48, 497, 10.1111/j.1528-1167.2007.00984.x

Errante, 2003, Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations, Seizure, 12, 300, 10.1016/S1059-1311(02)00295-9

Errington, 2006, Seeking a mechanism of action for the novel anticonvulsant lacosamide, Neuropharmacology, 50, 1016, 10.1016/j.neuropharm.2006.02.002

Errington, 2008, The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, Mol Pharmacol, 73, 157, 10.1124/mol.107.039867

Falcao, 2007, Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093), a new voltage-gated sodium channel blocker, Biopharm Drug Dispos, 28, 249, 10.1002/bdd.549

Fariello, 2007, Safinamide, Neurotherapeutics, 4, 110, 10.1016/j.nurt.2006.11.011

Fariello, 1998, Preclinical evaluation of PNU-151774E as a novel anticonvulsant, J Pharmacol Exp Ther, 285, 397

Feng, 2001, Brain microdialysis and PK/PD correlation of pregabalin in rats, Eur J Drug Metab Pharmacokinet, 26, 123, 10.1007/BF03190385

Ferron, 2003, Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects, Br J Clin Pharmacol, 56, 39, 10.1046/j.1365-2125.2003.01825.x

Ferron, 2002, Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers, J Clin Pharmacol, 42, 175, 10.1177/00912700222011210

Fischer, 2003, Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures, Clin Pharmacokinet, 42, 33, 10.2165/00003088-200342010-00002

Fisher, 2009, The anticonvulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator, Neuropharmacology, 56, 190, 10.1016/j.neuropharm.2008.06.004

Francois, 2008, Effects of carisbamate (RWJ-333369) in two models of genetically determined generalized epilepsy, the GAERS and the audiogenic Wistar AS, Epilepsia, 49, 393, 10.1111/j.1528-1167.2007.01278.x

Gebhardt, 2001, The antiepileptic drug losigamone decreases the persistent Na+ current in rat hippocampal neurons, Brain Res, 920, 27, 10.1016/S0006-8993(01)02863-3

Giraud, 2006, In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism, Drug Metab Dispos, 34, 608, 10.1124/dmd.105.007237

Hadad, 1997, Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide, Biopharm Drug Dispos, 18, 557, 10.1002/(SICI)1099-081X(199710)18:7<557::AID-BDD48>3.0.CO;2-D

Hempel, 1999, Metabolism of retigabine (D-23129), a novel anticonvulsant, Drug Metab Dispos, 27, 613

Hermann, 2003, Effects of age and sex on the disposition of retigabine, Clin Pharmacol Ther, 73, 61, 10.1067/mcp.2003.12

Hermann, 2003, Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects, Eur J Clin Pharmacol, 58, 795, 10.1007/s00228-003-0558-6

Heyn, 1994, Brain uptake and biotransformation of remacemide hydrochloride, a novel anticonvulsant, Drug Metab Dispos, 22, 443

Hiller, 1999, Retigabine N-glucuronidation and its potential role in enterohepatic circulation, Drug Metab Dispos, 27, 605

Hooper, 2001, Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males, Br J Clin Pharmacol, 51, 249, 10.1046/j.1365-2125.2001.00338.x

Howes, 2007, Talampanel, Neurotherapeutics, 4, 126, 10.1016/j.nurt.2006.11.001

Isoherranen, 2001, Anticonvulsant profile of valrocemide (TV1901): a new antiepileptic drug, Epilepsia, 42, 831, 10.1046/j.1528-1157.2001.042007831.x

Jones, 1999, The anticonvulsant effects of the enantiomers of losigamone, Br J Pharmacol, 128, 1223, 10.1038/sj.bjp.0702919

Kapetanovic, 1995, The effects of D-23129, a new experimental anticonvulsant drug, on neurotransmitter amino acids in the rat hippocampus in vitro, Epilepsy Res, 22, 167, 10.1016/0920-1211(95)00050-X

Kerrigan, 2000, Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial, Epilepsy Res, 42, 133, 10.1016/S0920-1211(00)00170-4

Knapp, 1998, Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy, J Child Neurol, 13, S15, 10.1177/0883073898013001051

Lai, 1995, Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin, Res Commun Mol Pathol Pharmacol, 88, 51

Langan, 2003, Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy, Epilepsia, 44, 46, 10.1046/j.1528-1157.2003.128902.x

Laxer, 2000, Assessment of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group, Epilepsia, 41, 1187, 10.1111/j.1528-1157.2000.tb00324.x

Leach, 1997, Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients, Seizure, 6, 179, 10.1016/S1059-1311(97)80003-9

Lees, 2006, Stereoselective effects of the novel anticonvulsant lacosamide against 4-AP induced epileptiform activity in rat visual cortex in vitro, Neuropharmacology, 50, 98, 10.1016/j.neuropharm.2005.08.016

LeTiran, 2002, Design and evaluation of affinity labels of functionalized amino acid anticonvulsants, J Med Chem, 45, 4762, 10.1021/jm020225f

Levy, 2008, Pharmacokinetics, safety, and tolerability of the new antiepileptic carisbamate in the elderly, Epilepsy Res, 79, 22, 10.1016/j.eplepsyres.2007.12.013

Levy, 1983, Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity, J Clin Pharmacol, 23, 523, 10.1002/j.1552-4604.1983.tb01799.x

Levy, 1984, Michaelis-Menten kinetics of stiripentol in normal humans, Epilepsia, 25, 486, 10.1111/j.1528-1157.1984.tb03448.x

Levy, 1984, Stiripentol kinetics in epilepsy: nonlinearity and interactions, Clin Pharmacol Ther, 36, 661, 10.1038/clpt.1984.237

Lodge, 1996, Stereoselective effects of 2,3-benzodiazepines in vivo: electrophysiology and neuroprotection studies, Neuropharmacology, 35, 1681, 10.1016/S0028-3908(96)00155-4

Maia, 2008, Effect of renal impairment on the pharmacokinetics of eslicarbazepine acetate, Int J Clin Pharmacol Ther, 46, 119, 10.5414/CPP46119

Maia, 2005, Effect of food on the pharmacokinetic profile of eslicarbazepine acetate (BIA 2-093), Drugs R D, 6, 201, 10.2165/00126839-200506040-00002

Malawska, 2005, New anticonvulsant agents, Curr Top Med Chem, 5, 69, 10.2174/1568026053386944

Mamidi, 2007, Metabolism and excretion of RWJ-333369 [1, 2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs, Drug Metab Dispos, 35, 566, 10.1124/dmd.106.012336

Mannens, 2007, The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2- carbamate, [S]-) in humans, Drug Metab Dispos, 35, 554, 10.1124/dmd.106.011940

Martire, 2004, M channels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals, J Neurosci, 24, 592, 10.1523/JNEUROSCI.3143-03.2004

Marzo, 2004, Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity, Pharmacol Res, 50, 77, 10.1016/j.phrs.2003.12.004

Matagne, 2008, Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A, Br J Pharmacol, 154, 1662, 10.1038/bjp.2008.198

Maurizis, 1997, Disposition and metabolism of 2,6-dimethylbenzamide N-(5-methyl-3-isoxazolyl) (D2916) in male and female rats, Drug Metab Dispos, 25, 33

Mawer, 1999, Adjustment of carbamazepine dose to offset the effects of the interaction with remacemide hydrochloride in a doubleblind, multicentre, add-on drug trial (CR2237) in refractory epilepsy, Epilepsia, 40, 190, 10.1111/j.1528-1157.1999.tb02074.x

Mazarati, 2002, Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus, Seizure, 11, 423, 10.1053/seiz.2002.0677

Monaghan, 1999, Ganaxolone: a novel positive allosteric modulator of the GABAA receptor complex for the treatment of epilepsy, Expert Opin Investig Drugs, 8, 1663, 10.1517/13543784.8.10.1663

Monaghan, 1997, Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity, Epilepsia, 38, 1026, 10.1111/j.1528-1157.1997.tb01486.x

Nohria, 2007, Ganaxolone, Neurotherapeutics, 4, 102, 10.1016/j.nurt.2006.11.003

Novak, 2007, Carisbamate (RWJ-333369), Neurotherapeutics, 4, 106, 10.1016/j.nurt.2006.11.016

Ogutu, 2003, Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus, Br J Clin Pharmacol, 56, 112, 10.1046/j.1365-2125.2003.01829.x

Otto, 2002, Effects of the anticonvulsant retigabine on cultured cortical neurons: changes in electroresponsive properties and synaptic transmission, Mol Pharmacol, 61, 921, 10.1124/mol.61.4.921

Palhagen, 2001, Rufinamide: a doubleblind, placebo-controlled proof of principle trial in patients with epilepsy, Epilepsy Res, 43, 115, 10.1016/S0920-1211(00)00185-6

Palmer, 1992, Biological profile of the metabolites and potential metabolites of the anticonvulsant remacemide, Epilepsy Res, 12, 9, 10.1016/0920-1211(92)90086-9

Parada, 2002, The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine, Neurochem Int, 40, 435, 10.1016/S0197-0186(01)00101-2

Parker, 2005, Stability and comparative metabolism of selected felbamate metabolites and postulated fluorofelbamate metabolites by postmitochondrial suspensions, Chem Res Toxicol, 18, 1842, 10.1021/tx050130r

Peeters, 1998, Pharmacokinetics of [14C]-labelled Losigamone and enantiomers after oral administration to healthy subjects, Eur J Drug Metab Pharmacokinet, 23, 45, 10.1007/BF03189826

Perucca, 2008, Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy, Epilepsia, 49, 1123, 10.1111/j.1528-1167.2008.01665.x

Perucca, 2002, Drugs in early clinical development, 913

Pieribone, 2007, Clinical evaluation of ganaxolone in pediatric and adolescent patients with refractory epilepsy, Epilepsia, 48, 1870, 10.1111/j.1528-1167.2007.01182.x

Poisson, 1984, A new type of anticonvulsant, stiripentol, Pharmacological profile and neurochemical study, Arzneimittelforschung, 34, 199

Pollard, 2008, Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy, Curr Opin Investig Drugs, 9, 101

Porter, 1995, Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential, J Neurochem, 64, 614, 10.1046/j.1471-4159.1995.64020614.x

Porter, 2007, Retigabine, Neurotherapeutics, 4, 149, 10.1016/j.nurt.2006.11.012

Pryor, 2001, Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses, Epilepsia, 42, 245

Quilichini, 2006, Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels, Epilepsia, 47, 704, 10.1111/j.1528-1167.2006.00497.x

Ram, 2001, A high-performance liquid chromatography-tandem mass spectrometric method for the determination of pharmacokinetics of ganaxolone in rat, monkey, dog and human plasma, J Chromatogr B Biomed Sci Appl, 751, 49, 10.1016/S0378-4347(00)00447-3

Richens, 2000, A placebo- controlled, double-blind cross-over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy, Seizure, 9, 537, 10.1053/seiz.2000.0447

Roecklein, 2007, Fluorofelbamate, Neurotherapeutics, 4, 97, 10.1016/j.nurt.2006.11.015

Rogawski, 2006, Diverse mechanisms of antiepileptic drugs in the development pipeline, Epilepsy Res, 69, 273, 10.1016/j.eplepsyres.2006.02.004

Rolan, 2008, The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men, Br J Clin Pharmacol, 66, 71, 10.1111/j.1365-2125.2008.03158.x

Rostock, 1996, D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures, Epilepsy Res, 23, 211, 10.1016/0920-1211(95)00101-8

Rundfeldt, 2000, Investigations into the mechanism of action of the new anticonvulsant retigabine, Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels, Arzneimittelforschung, 50, 1063

Salvati, 1999, Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound, J Pharmacol Exp Ther, 288, 1151

Sargentini-Maier, 2008, Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects, Drug Metab Dispos, 36, 36, 10.1124/dmd.107.017129

Sargentini-Maier, 2007, The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males, Br J Clin Pharmacol, 63, 680, 10.1111/j.1365-2125.2006.02829.x

Shen, 1992, Comparative anticonvulsant potency and pharmacokinetics of (+)-and (–)-enantiomers of stiripentol, Epilepsy Res, 12, 29, 10.1016/0920-1211(92)90088-B

Sills, 2002, Influence of cytochrome P450 induction on the pharmacokinetics and pharmacodynamics of remacemide hydrochloride, Epilepsy Res, 49, 247, 10.1016/S0920-1211(02)00049-9

Solyom, 2002, Non-competitive AMPA, antagonist of 2,3-benzodiazepine type, Curr Pharm Des, 8, 913, 10.2174/1381612024607081

Srinivasan, 1997, The effect of losigamone (AO-33) on electrical activity and excitatory amino acid release in mouse cortical slices, Br J Pharmacol, 122, 1490, 10.1038/sj.bjp.0701539

Stöhr, 2007, Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy, Epilepsy Res, 74, 147, 10.1016/j.eplepsyres.2007.03.004

Strolin Benedetti, 1994, The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats, J Pharm Pharmacol, 46, 814, 10.1111/j.2042-7158.1994.tb03736.x

Strolin Benedetti, 2003, Pharmacokinetics and metabolism of 14Clevetiracetam, a new antiepileptic agent, in healthy volunteers, Eur J Clin Pharmacol, 59, 621, 10.1007/s00228-003-0655-6

Subramaniam, 1996, Block of the N-methyl-D-aspartate receptor by remacemide and its des-glycine metabolite, J Pharmacol Exp Ther, 276, 161

Tatulian, 2001, Activation of expressed KCNQ potassium currents and native neuronalM-type potassium currents by the anti-convulsant drug retigabine, J Neurosci, 21, 5535, 10.1523/JNEUROSCI.21-15-05535.2001

Taylor, 1993, Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin, Epilepsy Res, 14, 11, 10.1016/0920-1211(93)90070-N

Tober, 1996, D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures, Eur J Pharmacol, 303, 163, 10.1016/0014-2999(96)00073-8

Torchin, 1996, Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes, Drug Metab Dispos, 24, 1002

Tran, 1997, Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants, Clin Pharmacol Ther, 62, 490, 10.1016/S0009-9236(97)90044-8

Tran, 1996, Effect of stiripentol on carbamazepine plasma concentration and metabolism in epileptic children, Eur J Clin Pharmacol, 50, 497, 10.1007/s002280050147

van Rijn, 2003, Synergy between retigabine and GABA in modulating the convulsant site of the GABAA receptor complex, Eur J Pharmacol, 464, 95, 10.1016/S0014-2999(03)01426-2

von Rosenstiel, 2007, Brivaracetam (UCB 34714), Neurotherapeutics, 4, 84, 10.1016/j.nurt.2006.11.004

Walton, 1999, Phenytoin penetration into brain after administration of phenytoin or fosphenytoin, Epilepsia, 40, 153, 10.1111/j.1528-1157.1999.tb02068.x

Wamil, 1996, Remacemide HCl and its metabolite, FPL 12495AA, limit action potential firing frequency and block NMDA responses of mouse spinal cord neurons in cell culture, Epilepsy Res, 23, 1, 10.1016/0920-1211(95)00053-4

Wang, 2003, A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin, Seizure, 12, 330, 10.1016/S1059-1311(03)00099-2

Wasserman, 2001, Stereoselective pharmacokinetic analysis and antiepileptic activity of N-2-hydroxypropyl valpromide, a central nervous system – active chiral valproylamide, Ther Drug Monit, 23, 414, 10.1097/00007691-200108000-00016

White, 2008, The anticonvulsant profile of rufi- namide (CGP 33101) in rodent seizure models, Epilepsia, 49, 1213, 10.1111/j.1528-1167.2008.01552.x

Wuttke, 2005, The new anticonvulsant retigabine favors voltagedependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate, Mol Pharmacol, 67, 1009, 10.1124/mol.104.010793

Yao, 2006, Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans, Epilepsia, 47, 1822, 10.1111/j.1528-1167.2006.00814.x

Zhang, 1994, Metabolic chiral inversion of stiripentol in the rat. I. Mechanistic studies, Drug Metab Dispos, 22, 544